FILE PHOTO: A woman holds a small bottle labeled with a

Inovio has rallied 860% year-to-date as investors bid up the company’s stock in hopes of the successful development of a vaccine for COVID-19.
On Tuesday, Inovio fell as much as 17.8% after the company released early Phase I data on its INO-4800 COVID-19 vaccine.
The company said 94% of Phase I participants demonstrated an immune response to the vaccine candidate.
Inovio said its vaccine candidate was selected to participate in a non-human primate study as part of the US government’s Operation Warp Speed.
Visit Business Insider’s homepage for more stories.

Inovio’s Tuesday morning release of early-stage data on its COVID-19 vaccine candidate sent shares lower by as much as 17.8%, giving the stock a breather after it rallied 860% year-to-date.

Investors have bid up the company on hopes that its vaccine candidate for COVID-19 proves successful in human trials.

The interim Phase 1 data from Inovio showed that 94% of trial participants demonstrated overall immune response at week six after two doses of INO-4800, according to the company.

Inovio said it plans to add older participants to its vaccine trial and to initiate a Phase 2/3 efficacy trial for INO-4800 later this summer, upon regulatory concurrence.

Read more:


Source:: Businessinsider – Finance

      

(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *